Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Health Professionals in Rheumatology Abstracts Oral Presentations Disease consequences OP0263-HPR MAJOR STRESSORS IN THE YEAR PRIOR TO RA DIAGNOSIS: IMPACT ON PATIENT-REPORTED OUTCOMES ONE YEAR LATER Free N. Andersen1, O. Schieir2, M. F. Valois1, G. Boire3, J. Pope4, G. Hazlewood5, L. Bessette6, C. Hitchon7, D. Tin8, C. Thorne8, E. Keystone2, V. Bykerk9, S. J.
Research Article B. D. A. Naafs Corresponding Author E-mail address: david.naafs@bristol.ac.uk https://orcid.org/0000-0001-5125-6928 Organic Geochemistry Unit, School of Chemistry and Cabot Institute, University of Bristol, Bristol, UK School of Earth Sciences, University of Bristol, Bristol, UK Correspondence to: B. D. A. Naafs, E-mail address: david.naafs@bristol.ac.uk Search for more papers by this author C.
There are conflicting data on comparative effectiveness of adalimumab and infliximab in patients with Crohn's disease (CD). To compare the effectiveness and safety of adalimumab and infliximab in biologic-naïve patients with CD, in a nationwide register-based propensity score-matched cohort study in Denmark. A total of 2908 Danish adults with CD had been treated with adalimumab or infliximab as their first biologic agent between 2005-2014.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
